Document is current
Any future updates will be listed below
-
Authors
Fang, Michael https://orcid.org/0000-0003-2849-1780
Hu, Jiaqi
Weiss, Jordan
Knopman, David S. https://orcid.org/0000-0002-6544-066X
Albert, Marilyn
Windham, B. Gwen
Walker, Keenan A. https://orcid.org/0000-0002-5989-9853
Sharrett, A. Richey
Gottesman, Rebecca F. https://orcid.org/0000-0002-9504-1256
Lutsey, Pamela L.
Mosley, Thomas
Selvin, Elizabeth https://orcid.org/0000-0002-3539-2070
Coresh, Josef https://orcid.org/0000-0002-4598-0669
- License Information
-
More Information
Article History
Received: 15 May 2024
Accepted: 3 October 2024
First Online: 13 January 2025
Competing interests
: D.S.K. has no disclosures relevant to the current work. D.S.K. serves on a Data Safety Monitoring Board for the Dominantly Inherited Alzheimer Network Treatment Unit study. He was an investigator in Alzheimer clinical trials sponsored by Biogen, Eli Lilly Pharmaceuticals and the University of Southern California and is currently an investigator in a trial in frontotemporal degeneration with Alector. He has served as a consultant for Roche, AriBio, Linus Health, Biovie and Alzeca Biosciences but receives no personal compensation. He receives funding from the NIH. The other authors declare no competing interests.
